6945.TWO AP Biosciences Inc

Healthcare Biotechnology Taiwan OTC Exchange
112.00 TWD
Close of Nov 6, 2026
86.10 236.00
Market cap
TWD 10.7B
P/E
-
P/B
4.77x
ROE
-18.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6945.TWO undervalued?

Graham number

The Graham number of AP Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AP Biosciences Inc fundamental analysis

No fundamental analysis for AP Biosciences Inc yet.

AP Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AP Biosciences Inc

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical res…

Full company profile